Chen Xu-jian, Wu Li-min, Xu Xiao-bo, Feng Xiao-wen, Xie Hai-yang, Zhang Min, Shen Yan, Wang Wei-lin, Liang Ting-bo, Zheng Shu-sen
Key Laboratory of Combined Multi-Organ Transplantation, the First Affiliated Hospital, Zhejiang University, Hangzhou 310003, China.
Zhonghua Wai Ke Za Zhi. 2007 Oct 1;45(19):1354-8.
To study the expression of Polo-like kinase 1 (PLK1) and E-cadherin in the tissues of hepatocellular carcinoma, and to discuss the relationship between them and clinical-pathological features, and to evaluate their prognostic value of hepatocellular carcinoma after liver transplantation.
mRNA and protein expression of PLK1, E-cadherin were detected by RT-PCR and immunohistochemistry method respectively, the correlations of them with clinical-pathological data, tumor free time, recurrence rate were compared and analyzed.
The mRNA expression was observed in 90.0% for PLK1 and 96.0% for E-cadherin, and higher in cancerous' tissues than paracancerous' of all cases for PLK1 but no trend for E-cadherin. The positive and decreased expression rate for PLK1 and E-cadherin was observed in 60.0% and 50.0% respectively, the positive PLK1 expression was correlated with preoperative serum alpha-fetoprotein (AFP) only (chi2 = 4.433, P = 0.035), while E-cadherin expression was associated with none of the clinical-pathological features. There was a correlation between the positive PLK1 and decreased E-cadherin expression (chi2 = 5.333, P = 0.021). PLK1 (P = 0.006), E-cadherin (P = 0.019) and larger tumor (P = 0.019), portal vein tumor thrombi (P = 0.030), Edmondson grading (P = 0.019), preoperative serum AFP (P = 0.020) were all correlated with recurrence rate under Kaplan-Meier analysis, while only PLK1 (RR = 3.104, P = 0.009) had significant difference under Cox regression analysis.
The positive PLK1 expression and the decreased E-cadherin expression indicate higher recurrence rate of HCC after liver transplantation, and PLK1 is a independent risk factor.
研究Polo样激酶1（PLK1）和E-钙黏蛋白在肝细胞癌组织中的表达情况，探讨它们与临床病理特征的关系，并评估其对肝移植术后肝细胞癌的预后价值。
分别采用逆转录聚合酶链反应（RT-PCR）和免疫组织化学方法检测PLK1、E-钙黏蛋白的mRNA和蛋白表达，比较分析它们与临床病理数据、无瘤生存时间、复发率的相关性。
所有病例中PLK1的mRNA表达率为90.0%，E-钙黏蛋白为96.0%；PLK1在所有病例癌组织中的表达高于癌旁组织，而E-钙黏蛋白无此趋势。PLK1和E-钙黏蛋白的阳性及低表达率分别为60.0%和50.0%，PLK1阳性表达仅与术前血清甲胎蛋白（AFP）相关（χ2 = 4.433，P = 0.035），而E-钙黏蛋白表达与任何临床病理特征均无关。PLK1阳性表达与E-钙黏蛋白低表达之间存在相关性（χ2 = 5.333，P = 0.021）。根据Kaplan-Meier分析，PLK1（P = 0.006）、E-钙黏蛋白（P = 0.019）、肿瘤较大（P = 0.019）、门静脉癌栓（P = 0.030）、Edmondson分级（P = 0.019）、术前血清AFP（P = 0.020）均与复发率相关，而根据Cox回归分析，只有PLK1（RR = 3.104，P = 0.009）有显著差异。
PLK1阳性表达和E-钙黏蛋白低表达提示肝移植术后肝细胞癌复发率较高，且PLK1是独立危险因素。
